Retinal vein occlusion (RVO) affects more 16 millions people worldwide. The main causes of vision loss are swelling in the retina, poor blood supply and complications from abnormal blood vessels growth. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) drugs are often injected into the eye to treat the swelling in the retina. The long-term effect of these anti-VEGF drugs on the retinal vessels is not known. A new technique to image the retina involves optical coherence tomography angiography (OCTA) that allows us to take pictures of the different layers of vessels in the retina. This can be done without having to inject any dye into the patient. Our study uses OCTA to examine changes in the blood supply of the retina in patients receiving anti-VEGF for treatment of RVO.
|Effective start/end date||7/1/18 → 12/30/20|
- Illinois Society for the Prevention of Blindness (AGMT 7/26/18)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.